Mantle cell lymphoma physical examination: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overview== | ==Overview== | ||
Common physical examination findings of mantle cell lymphoma include [[fever]], [[rash]], [[splenomegaly]], [[hepatomegaly]],[[Lymphadenopathy| | Common physical examination findings of mantle cell lymphoma include [[fever]], [[rash]], [[splenomegaly]], [[hepatomegaly]], [[Lymphadenopathy|peripheral lymphadenopathy]], and [[Lymphadenopathy|central lymphadenopathy]]. | ||
==Physical Examination<ref name="seer">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref>== | ==Physical Examination<ref name="seer">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref>== | ||
===Temperature=== | ===Temperature=== | ||
Revision as of 20:24, 2 September 2015
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma physical examination On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma physical examination |
|
Risk calculators and risk factors for Mantle cell lymphoma physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Common physical examination findings of mantle cell lymphoma include fever, rash, splenomegaly, hepatomegaly, peripheral lymphadenopathy, and central lymphadenopathy.
Physical Examination[1]
Temperature
- Fever is often present
Skin
Neck
Thorax
- Thoracic masses suggestive of central lymphadenopathy
- Chest tenderness
Abdomen
- Abdominal masses suggestive of central lymphadenopathy
- Splenomegaly
- Hepatomegaly
- Abdominal tenderness
Extremities
- Peripheral lymphadenopathy
- Bone tenderness
References
- ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov